With the introduction of LTCI, we are witnessing definite improvements in clinical presentation of our FeLV+ cats
Scottsdale, Arizona (PRWEB) March 5, 2008
IMULAN BioTherapeutics officially launched Lymphocyte T-Cell Immunomodulator (LTCI), the first and only approved treatment aid in the United States for Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV) infections. LTCI has shown to have positive benefits on the health of cats infected with these notorious viral diseases.
FeLV and FIV infections, sometimes referred to as feline aids, are two of the most common and fatal feline diseases worldwide. Infections can cause severe immune suppression, anemia, and result in increased risk of other infections.
Dr. Craig Woods, CEO of IMULAN stated, "IMULAN is pleased to be the exclusive distributor of LTCI, an example of our commitment to providing innovative products for diseases where no other approved treatment exists."
LTCI is a naturally occurring immune stimulating protein that helps restore a cat's ability to fight infection by increasing the production of lymphocytes. Lymphocytes are immune cells that help the body identify and destroy viruses and certain cancers.
"With the introduction of LTCI, we are witnessing definite improvements in clinical presentation of our FeLV+ cats," stated Aimée Zelman, DVM. "There have been absolutely no adverse side effects. The quality of life for these FeLV infected cats has been dramatically improved with their LTCI injections."
LTCI is only available through licensed veterinarians in the United States. Pet owners are encouraged to contact their veterinarian for additional information about LTCI.
For additional information on LTCI or IMULAN, please call 877-892-9595 or visit http://www.IMULAN.com.
About Lymphocyte T-Cell Immunomodulator: LTCI is a conditionally approved treatment aid for cats infected with Feline Leukemia Virus (FeLV) and/or Feline Immunodeficiency Virus (FIV). Conditional licenses are granted by the United States Department of Agriculture Center for Veterinary Biologics to products that have met reasonable expectation of efficacy, have demonstrated purity, and passed safety testing. LTCI is manufactured by T-Cyte Therapeutics, Inc. and is exclusively distributed by IMULAN BioTherapeutics, LLC.
About IMULAN BioTherapeutics: IMULAN is a privately held bioscience company focused on providing innovative solutions for complex animal diseases. IMULAN's policy is to provide veterinarians access to conditionally approved products for diseases where no current approved therapy is available. IMULAN's products give animal owners better solutions for their pet's diseases.
Dr. Craig Woods, CEO
cwoods @ imulan.com